2d • General discussion
🧬 Retatrutide: Redefining Weight Loss Efficacy – A Quick Breakdown
The Evolution
- Semaglutide (GLP-1): ~15% weight loss
- Tirzepatide (GLP-1/GIP): ~21% weight loss
- Retatrutide (GLP-1/GIP/Glucagon): rivals bariatric surgery
The Data
- Phase 2 (12 mg): 24.2% weight loss at 48 weeks; 64% achieved ≥20%
- Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks; 58.6% achieved ≥25%
- Network meta-analysis: 3.2% greater than tirzepatide, 9.9% > semaglutide
Beyond Weight Loss
- HbA1c reduction: 2.16% at 36 weeks; 82% reached ≤6.5%
- Knee osteoarthritis pain: WOMAC reduction of 4.5 points
- 82% reduction in hepatic steatosis
- Blood pressure, lipids, and liver fat improvements
- Preclinical: 14-fold reduction in pancreatic tumor volume
Safety
- GI side effects (nausea, diarrhea, vomiting)
- Discontinuation rate (12 mg): 18.2%
- Higher adverse event risk than dual agonists
Takeaway
Retatrutide represents a significant advancement in metabolic research. Triple agonist mechanism offers synergistic benefits.
⚠️ Research only. Not for human consumption.
0
0 comments
🧬 Retatrutide: Redefining Weight Loss Efficacy – A Quick Breakdown
powered by
skool.com/biohacking-and-longevity-group-3757
All-in-one peptide education community. 🧪
Dosing guides, storage protocols, stacking frameworks, vendor intel, GLP-1 research, and expert support.🧬
Suggested communities
Powered by